Understanding the link between cancer and muscle diseases
Prediction and Significance of Cancer in Idiopathic Inflammatory Myositis
This study is looking at how muscle weakness from idiopathic inflammatory myopathies (IIM) might be linked to a higher risk of cancer, and it hopes to find specific markers in the blood that could help predict cancer in people with IIM, making cancer screenings easier and more effective for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10855717 on NIH RePORTER |
What this research studies
This research investigates the connection between idiopathic inflammatory myopathies (IIM), a group of autoimmune diseases that cause muscle weakness, and the risk of developing cancer. It aims to identify specific autoantibodies that may serve as biomarkers for predicting cancer in patients with IIM. By studying the relationship between cancer emergence and IIM outcomes, the research seeks to improve current cancer screening practices, which can be costly and lead to unnecessary procedures. The findings could provide valuable insights into how cancer affects muscle disease and vice versa.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic inflammatory myopathies who may be at risk for developing cancer.
Not a fit: Patients without a diagnosis of idiopathic inflammatory myopathies or those who do not have any associated cancer risk may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate cancer predictions for patients with muscle diseases, potentially reducing unnecessary screenings and improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in understanding the relationship between autoimmune diseases and cancer, but this specific approach is relatively novel.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Mecoli, Christopher — Johns Hopkins University
- Study coordinator: Mecoli, Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.